Literature DB >> 11705886

Bimodal effects of 1R,2R-diaminocyclohexane(trans-diacetato)(dichloro)platinum(IV) on cell cycle checkpoints.

J Kuang1, G He, Z Huang, A R Khokhar, Z H Siddik.   

Abstract

1R,2R-Diaminocyclohexane(trans-diacetato)(dichloro)-platinum(IV) (DACH-acetato-Pt) is a novel platinum-based agent that is highly effective against cisplatin-resistant ovarian tumor cells. To probe its cellular mechanism, the effects of DACH-acetato-Pt (0-6.4 microM) on cell cycle checkpoints were examined using the ovarian cancer A2780 cell line as the model system. We found that DACH-acetato-Pt at > or =0.2 microM dramatically inhibited cell growth and induced cell death. At concentrations < or =0.6 microM (low effective concentrations), DACH-acetato-Pt specifically induced G(1) phase arrest by selectively inhibiting cyclin-dependent kinase 4 (Cdk4) and Cdk2 activities. The Cdc2 activity, which regulates G(2)-M phase progression, was unaffected by the drug at these concentrations. At concentrations >0.6 microM (high effective concentrations), DACH-acetato-Pt first transiently inhibited S-phase progression and then blocked cell cycle progression at both G(1) and G(2) phases. These cell cycle effects were associated with sequential inhibitions of Cdk2/cyclin A activity, Cdk4 and Cdk2 activities, and Cdc2 kinase activity. Following the cell cycle effects, both the low and high effective concentrations of DACH-acetato-Pt induced cell death through apoptosis. These results indicate that DACH-acetato-Pt activates multiple cell cycle checkpoints in a bimodal manner and suggest that the cell cycle effects demonstrated in these studies may be linked to its ability to induce apoptosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11705886

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  6 in total

1.  The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog.

Authors:  Guangan He; Jian Kuang; Abdul R Khokhar; Zahid H Siddik
Journal:  Gynecol Oncol       Date:  2011-05-18       Impact factor: 5.482

2.  Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.

Authors:  Xiaolei Xie; Guangan He; Zahid H Siddik
Journal:  Mol Pharmacol       Date:  2020-02-16       Impact factor: 4.436

3.  Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents.

Authors:  Guangan He; Xiaolei Xie; Zahid H Siddik
Journal:  Cancer Chemother Pharmacol       Date:  2020-05-28       Impact factor: 3.333

4.  Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21.

Authors:  G He; J Kuang; Z Huang; J Koomen; R Kobayashi; A R Khokhar; Z H Siddik
Journal:  Br J Cancer       Date:  2006-11-07       Impact factor: 7.640

5.  Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53.

Authors:  X Xie; G Lozano; Z H Siddik
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

6.  Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents.

Authors:  G He; J Kuang; J Koomen; R Kobayashi; A R Khokhar; Z H Siddik
Journal:  Br J Cancer       Date:  2013-10-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.